Portal de Periódicos da CAPES

Bloodless medicine: clinical care without allogeneic blood transfusion

2003; Wiley; Volume: 43; Issue: 5 Linguagem: Inglês

10.1046/j.1537-2995.2003.00367.x

1537-2995

Lawrence T. Goodnough, Aryeh Shander, Ríchard K. Spence,

Trauma, Hemostasis, Coagulopathy, Resuscitation

TransfusionVolume 43, Issue 5 p. 668-676 Bloodless medicine: clinical care without allogeneic blood transfusion Lawrence T. Goodnough, Lawrence T. Goodnough From the Washington University School of Medicine, St. Louis, Missouri; Mount Sinai School of Medicine, Mount Sinai Hospital, New York, New York; Department Anesthesiology, Critical Care and Hyperbaric Medicine, Englewood Hospital and Medical Center, Englewood, New Jersey; School of Health Related Professions, University of Alabama, Birmingham, Alabama.Search for more papers by this authorAryeh Shander, Aryeh Shander From the Washington University School of Medicine, St. Louis, Missouri; Mount Sinai School of Medicine, Mount Sinai Hospital, New York, New York; Department Anesthesiology, Critical Care and Hyperbaric Medicine, Englewood Hospital and Medical Center, Englewood, New Jersey; School of Health Related Professions, University of Alabama, Birmingham, Alabama.Search for more papers by this authorRichard Spence, Richard Spence From the Washington University School of Medicine, St. Louis, Missouri; Mount Sinai School of Medicine, Mount Sinai Hospital, New York, New York; Department Anesthesiology, Critical Care and Hyperbaric Medicine, Englewood Hospital and Medical Center, Englewood, New Jersey; School of Health Related Professions, University of Alabama, Birmingham, Alabama.Search for more papers by this author Lawrence T. Goodnough, Lawrence T. Goodnough From the Washington University School of Medicine, St. Louis, Missouri; Mount Sinai School of Medicine, Mount Sinai Hospital, New York, New York; Department Anesthesiology, Critical Care and Hyperbaric Medicine, Englewood Hospital and Medical Center, Englewood, New Jersey; School of Health Related Professions, University of Alabama, Birmingham, Alabama.Search for more papers by this authorAryeh Shander, Aryeh Shander From the Washington University School of Medicine, St. Louis, Missouri; Mount Sinai School of Medicine, Mount Sinai Hospital, New York, New York; Department Anesthesiology, Critical Care and Hyperbaric Medicine, Englewood Hospital and Medical Center, Englewood, New Jersey; School of Health Related Professions, University of Alabama, Birmingham, Alabama.Search for more papers by this authorRichard Spence, Richard Spence From the Washington University School of Medicine, St. Louis, Missouri; Mount Sinai School of Medicine, Mount Sinai Hospital, New York, New York; Department Anesthesiology, Critical Care and Hyperbaric Medicine, Englewood Hospital and Medical Center, Englewood, New Jersey; School of Health Related Professions, University of Alabama, Birmingham, Alabama.Search for more papers by this author First published: 16 April 2003 https://doi.org/10.1046/j.1537-2995.2003.00367.xCitations: 115 Address reprint requests to: Lawrence T. Goodnough, MD, Professor of Medicine and Pathology and Immunology, Division of Laboratory Medicine, Box 8118, 660 S. Euclid Avenue, St. Louis, MO 63110-1093; e-mail: [email protected] .edu. ABBREVIATIONS: ANH = acute normovolemic hemodilution; AOC(s) = artificial oxygen carrier(s); PAD = preoperative autologous blood donation. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Circular of information for the use of human blood and blood components. Bethesda: American Association of Blood Banks, America's Blood Centers, and American Red Cross; 2000. 2 Goodnough LT, Shander A, Brecher ME. Transfusion medicine: looking to the future. Lancet 2003; 361: 161-9. 3 Zumberg MS, Procter JL, Lottenberg R, Kitchens CS, Klein HG. Autoantibody formation in the alloimmunized red blood cell recipient: clinical and laboratory implications. Arch Intern Med 2001; 161: 285-90. 4 Hebert PC, Wells G, Blajchman MA. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators and the Canadian Critical Care Trials Group. N Engl J Med 1999; 340: 409-17. 5 Carson JL, Noveck H, Berlin JA, Gould SA. Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. Transfusion 2002; 42: 812-8. 6 Hutchinson AB, Fergusson D, Graham ID, et al. Utilization of technologies to reduce allogeneic blood transfusion in the United States. Transfus Med 2001; 11: 79-85. 7 Goodnough LT, Monk TG, Andriole GL. Erythropoietin therapy. N Engl J Med 1997; 336: 933-8. 8 Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross donor population. Transfusion 2002; 42: 975-9. 9 Centers for Disease Control. Investigations of West Nile virus infections in recipients of blood transfusions. MMWR 2002; 51: 1-2. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/dispatch_westnile.htm 10 Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. First of two parts—blood transfusion. N Engl J Med 1999; 340: 438-47. 11 Krombach J, Kampe S, Gathof BS, Diefenbach C, Kasper SM. Human error: the persisting risk of blood transfusion. A report of five cases. Anesth Analg 2002; 94: 154-6. 12 Spahn DR, Casutt M. Eliminating blood transfusions: new aspects and perspectives. Anesthesiology 2000; 93: 242-55. 13 Van der Linden P, De Hert S, Daper A, et al. A standardized multidisciplinary approach reduces the use of allogeneic blood products in patients undergoing cardiac surgery. Can J Anaesth 2001; 48: 894-901. 14 Wittmann PH, Wittmann FW. Total hip replacement surgery without blood transfusion in Jehovah's Witnesses. Br J Anaesth 1992; 68: 306-7. 15 Helm RE, Rosengart TK, Gomez M, et al. Comprehensive multimodality blood conservation: 100 consecutive CABG operations without transfusion. Ann Thorac Surg 1998; 65: 125-36. 16 Smoller BR, Kruskall MS. Phlebotomy for diagnostic laboratory tests in adults: pattern of use and effect on transfusion requirements. N Engl J Med 1986; 314: 1233-5. 17 Brecher ME, Goodnough LT. The rise and fall of preoperative autologous blood donation. Transfusion 2001; 41: 1459-62. 18 Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. Second of two parts—blood conservation. N Engl J Med 1999; 340: 525-33. 19 Goldman M, Savard R, Long A, Gelinas S, Germain M. Declining value of preoperative autologous donation. Transfusion 2002; 42: 819-23. 20 Forgie M, Wells P, Laupacis A, Fergusson D. Preoperative autologous donation decreases allogeneic transfusion but increases exposure to all red cell transfusion: results of a meta-analysis. International Study of Perioperative Transfusion (ISPOT) Investigators. Arch Intern Med 1998; 158: 610-6. 21 Kurtz SB, Frost DB. A comparison of two surgical techniques for performing mastectomy. Eur J Surg Oncol 1995; 21: 143-5. 22 Braswell C, Campos J, Spence RK. Reducing operative blood loss during hepatic surgery: from the middle ages to the space age. Curr Surg 2001; 58: 472-7. 23 Fasulo F, Giori A, Fissi S, et al. Cavitron ultrasonic surgical aspirator (CUSA) in liver resection. Int Surg 1992; 77: 64-6. 24 Une Y, Uchino J, Shimamura T, et al. Water jet scalpel for liver resection in hepatocellular carcinoma with or without cirrhosis. Int Surg 1996; 81: 45-8. 25 Wang GJ, Hungerford DS, Savory CG, et al. Use of fibrin sealant to reduce bloody drainage and hemoglobin loss after total knee arthroplasty: a brief note on a randomized prospective trial. J Bone Joint Surg Am 2001; 83-A: 1503-5. 26 Spence RK, Cernaianu AC, De Carson JI, Rossi AJ. Transfusion and surgery. Curr Probl Surg 1993; 30: 1101-80. 27 Schneeberger AG, Schulz RF, Ganz R. Blood loss in total hip arthroplasty: lateral position combined with preservation of the capsule versus supine position combined with capsulectomy. Arch Orthop Trauma Surg 1998; 117: 47-9. 28 Moore EE, Burch JM, Franciose RJ, et al. Staged physiologic restoration and damage control surgery. World J Surg 1998; 22: 1184-91. 29 Schmied H, Schiferer A, Sessler DI, Meznik C. The effects of red-cell scavenging, hemodilution, and active warming on allogenic blood requirements in patients undergoing hip or knee arthroplasty. Anesth Analg 1998; 86: 387-91. 30 Goodnough LT, Monk TG, Brecher ME. Acute normovolemic hemodilution should replace the preoperative donation of autologous blood as a method of autologous-blood procurement. Transfusion 1998; 38: 473-6. 31 Matot I, Scheinin O, Jurim O, Eid A. Effectiveness of acute normovolemic hemodilution to minimize allogeneic blood transfusion in major liver resections. Anesthesiology 2002; 97: 794-800. 32 Monk TG, Goodnough LT, Birkmeyer JD, et al. Acute normovolemic hemodilution is a cost-effective alternative to preoperative autologous blood donation by patients undergoing radical retropubic prostatectomy. Transfusion 1995; 35: 559-65. 33 Thomas MJ. Infected and malignant fields are an absolute contraindication to intraoperative cell salvage: fact or fiction? Transfus Med 1999; 9: 269-78. 34 Rebarber A, Lonser R, Jackson S, et al. The safety of intraoperative autologous blood collection and autotransfusion during cesarean section. Am J Obstet Gynecol 1998; 179: 715-20. 35 Waters JH, Biscotti C, Potter PS, Phillipson E. Amniotic fluid removal during cell salvage in the cesarean section patient. Anesthesiology 2000; 92: 1531-6. 36 Gray CL, Amling CL, Polston GR, et al. Intraoperative cell salvage in radical retropubic prostatectomy. Urology 2001; 58: 740-5. 37 Mirhashemi R, Averette HE, Deepika K, et al. The impact of intraoperative autologous blood transfusion during type III radical hysterectomy for early-stage cervical cancer. J Obstet Gynecol 1999; 181: 1310-6. 38 Hansen E, Knuechel R, Altmeppen J, Taeger K. Blood irradiation for intraoperative autotransfusion in cancer surgery: demonstration of efficient elimination of contaminating tumor cells. Transfusion 1999; 39: 608-15. 39 Huet C, Salmi LR, Fergusson D, et al. A meta-analysis of the effectiveness of cell salvage to minimize perioperative allogeneic blood transfusion in cardiac and orthopedic surgery. International Study of Perioperative Transfusion (ISPOT) Investigators. Anesth Analg 1999; 89: 861-9. 40 Goodnough LT, Monk TG, Sicard G, et al. Intraoperative salvage in patients undergoing elective abdominal aneurysm repair: an analysis of costs and benefits. J Vasc Surg 1996; 24: 213-8. 41 Hebert PC, Yetisir E, Martin C, et al. Is a low transfusion threshold safe in patients with cardiovascular disease? Crit Care Med 2001; 29: 227-34. 42 Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood 2000; 96: 823-33. 43 Goodnough LT, Brittenham G. Limitations of the erythropoietic response to serial phlebotomy: implications for autologous blood donor programs. J Lab Clin Med 1990; 115: 38-35. 44 Goodnough LT, Price TH, Rudnick S, Soegiarso RW. Preoperative red cell production in patients undergoing aggressive autologous blood phlebotomy with and without erythropoietin therapy. Transfusion 1992; 32: 441-5. 45 Goodnough LT, Verbrugge D, Marcus RE, Goldberg V. The effect of patient size and dose of recombinant human erythropoietin therapy on red blood cell expansion. J Am Coll Surg 1994; 179: 171-6. 46 Goodnough LT, Price TH, Parvin CA. The endogenous erythropoietin response and the erythropoietic response to blood loss anemia: the effects of age and gender. J Lab Clin Med 1995; 126: 57-64. 47 Goodnough LT, Marcus RE. Erythropoiesis in patients stimulated with erythropoietin: the relevance of storage iron. Vox Sang 1998; 75: 128-33. 48 Goodnough LT, Price TH, Parvin CA, et al. Erythropoietin response to anaemia is not altered by surgery or recombinant human erythropoietin therapy. Br J Haematol 1994; 87: 695-9. 49 Coleman PH, Stevens AR, Dodge HT, Finch CA. Rate of blood regeneration after blood loss. Arch Intern Med 1953; 92: 341-8. 50 Crosby WH. Treatment of hemochromatosis by energetic phlebotomy: one patient's response to getting 55 liters of blood in 11 months. Br J Haematol 1958; 4: 82-8. 51 Goodnough LT, Merkel K. The use of parenteral iron and recombinant human erythropoietin therapy to stimulate erythropoiesis in patients undergoing repair of hip fracture. Int J Hematol 1996; 1: 163-6. 52 Finch CA. Erythropoiesis, erythropoietin, and iron. Blood 1982; 60: 1241-6. 53 Muirhead N, Bargman J, Burgess E, et al. Evidence-based recommendations for the clinical use of recombinant hu- man erythropoietin. Am J Kidney Dis 1995; 26 Suppl 1: S1-24. 54 Kaisi M, Ngwalle EWK, Runyoro DE, Rogers J. Evaluation and tolerance of response to iron dextran (Imferon) administered by total dose infusion to pregnant women with iron deficiency anemia. Int J Gynecol Obstet 1988; 26: 235-43. 55 Mays T, Mays T. Intravenous iron dextran therapy in the treatment of anemia occurring in surgical, gynecologic, and obstetric patients. Surg Gynecol Obstet 1976; 143: 381. 56 Hillman RS, Henderson PA. Control of marrow production by the level of iron supply. J Clin Invest 1969; 48: 454-60. 57 Henderson PA, Hillman RS. Characteristics of iron dextran utilization in man. Blood 1969; 34: 357-75. 58 Winslow RM. Blood substitutes—a moving target. Nat Med 1995; 1: 1212-5. 59 Stowell CP, Levin J, Spiess BD, Winslow RM. Progress in the development of RBC substitutes. Transfusion 2001; 41: 287-99. 60 Ma Z, Monk TG, Goodnough LT, et al. Effect of hemoglobin- and perflubron-based oxygen carriers on common clinical laboratory tests. Clin Chem 1997; 43: 1732-7. 61 Scott MG, Kucik DF, Goodnough LT, Monk TG. Blood substitutes: evolution and future applications. Clin Chem 1997; 43: 1724-31. 62 O'Hara JF, Colburn WA, Tetzlaff JE, et al. Hemoglobin and methemoglobin concentration after large-dose infusion of diaspirin cross-linked hemoglobin. Anesth Analg 2001; 92: 44-8. 63 Rioux F, Drapeau G, Marceau F. Recombinant human hemoglobin (rHb 1.1) selectively inhibits vasorelaxation elicited by nitric oxide donors in rabbit isolated aortic rings. J Cardiovasc Pharmacol 1995; 25: 587-94. 64 Winslow RM. Blood substitutes. Curr Opin Hematol 2002; 9: 146-51. 65 Kasper SM, Grune F, Walter M, et al. The effects of increased doses of bovine hemoglobin on hemodynamics and oxygen transport in patients undergoing preoperative hemodilution for elective abdominal aortic surgery. Anesth Analg 1998; 87: 284-91. 66 Sloan EP, Koenigsberg M, Gens D, et al. Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial. JAMA 1999; 282: 1857-64. 67 Keipert PE. Use of Oxygent, a perfluorochemical-based oxygen carrier, as an alternative to intraoperative blood transfusion. Artif Cells Blood Substi Immobil Biotechnol 1995; 23: 381-94. 68 Spahn DR, Van Brempt R, Theilmeier G, et al. Perflubron emulsion delays blood transfusions in orthopedic surgery. European Perflubron Emulsion Study Group. Anesthesiology 1999; 91: 1195-208. 69 Jones JA. Red blood cell substitutes: current status. Br J Anaesthes 1995; 74: 697-703. 70 Maguire PJ, Stevens C, Humes HD, et al. Bioartificial organ support for hepatic, renal, and hematologic failure. Crit Care Clin 2000; 16: 681-4. 71 Spahn DR, Leone BJ, Reves JG, Pasch T. Cardiovascular and coronary physiology of acute isovolemic hemodilution: a review of nonoxygen-carrying and oxygen-carrying solutions. Anesth Analg 1994; 78: 1000-21. 72 Cothren C, Moore EE, Offner PJ, Haenel JB, Johnson JL. Blood substitute and erythropoietin therapy in a severely injured Jehovah's Witness. N Engl J Med 2002; 346: 1097-8. 73 Brecher ME, Goodnough LT, Monk T. The value of oxygen-carrying solutions in the operative setting, as determined by mathematical modeling. Transfusion 1999; 39: 396-402. 74 Mullon J, Giacoppe G, Clagett C, McCune D, Dillard T. Transfusions of polymerized bovine hemoglobin in a patient with severe autoimmune hemolytic anemia. N Engl J Med 2000; 342: 1638-43. 75 Klein HG. The prospects for red cell substitutes. N Engl J Med 2001; 342: 1666-8. 76 Raff JP, Dobson CE, Tsai HM. Transfusion of polymerised human haemoglobin in a patient with severe sickle-cell anemia. Lancet 2002; 360: 464-5. 77 Reiter CD, Wang X, Tranus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002; 8: 1383-9. Citing Literature Volume43, Issue5May 2003Pages 668-676 ReferencesRelatedInformation